» Articles » PMID: 18774188

The Healthy Cell Bias of Estrogen Action: Mitochondrial Bioenergetics and Neurological Implications

Overview
Journal Trends Neurosci
Specialty Neurology
Date 2008 Sep 9
PMID 18774188
Citations 187
Authors
Affiliations
Soon will be listed here.
Abstract

The 'healthy cell bias of estrogen action' hypothesis examines the role that regulating mitochondrial function and bioenergetics play in promoting neural health and the mechanistic crossroads that lead to divergent outcomes following estrogen exposure. Estrogen-induced signaling pathways in hippocampal and cortical neurons converge upon the mitochondria to enhance aerobic glycolysis coupled to the citric acid cycle, mitochondrial respiration and ATP generation. Convergence of estrogen-induced signaling onto mitochondria is also a point of vulnerability when activated in diseased neurons which exacerbates degeneration through increased load on dysregulated calcium homeostasis. As the continuum of neurological health progresses from healthy to unhealthy so too do the benefits of estrogen or hormone therapy. The healthy cell bias of estrogen action hypothesis provides a lens through which to assess disparities in outcomes across basic and clinical science and on which to predict outcomes of estrogen interventions for sustaining neurological health and preventing age-associated neurodegenerative diseases such as Alzheimer's.

Citing Articles

Sex differences in age-associated neurological diseases-A roadmap for reliable and high-yield research.

Bonkhoff A, Coughlan G, Perosa V, Alhadid K, Schirmer M, Regenhardt R Sci Adv. 2025; 11(10):eadt9243.

PMID: 40043111 PMC: 11881909. DOI: 10.1126/sciadv.adt9243.


DNA methylation, histone acetylation in the regulation of memory and its modulation during aging.

Singh P, Paramanik V Front Aging. 2025; 5():1480932.

PMID: 39835300 PMC: 11743476. DOI: 10.3389/fragi.2024.1480932.


Menopausal hormone therapy is associated with worse levels of Alzheimer's disease biomarkers in APOE ε4-carrying women: An observational study.

Jauregi-Zinkunegi A, Gleason C, Bendlin B, Okonkwo O, Hermann B, Blennow K Alzheimers Dement. 2025; 21(2):e14456.

PMID: 39783876 PMC: 11848176. DOI: 10.1002/alz.14456.


and Chronic Health Risk Factors are Associated with Sex-Specific Preclinical Alzheimer's Disease Neuroimaging Biomarkers.

Losinski G, Key M, Vidoni E, Clutton J, Morris J, Burns J medRxiv. 2024; .

PMID: 39606325 PMC: 11601779. DOI: 10.1101/2024.11.21.24317732.


The aged female rhesus macaque as a translational model for human menopause and hormone therapy.

Kohama S, Urbanski H Horm Behav. 2024; 166:105658.

PMID: 39531811 PMC: 11602343. DOI: 10.1016/j.yhbeh.2024.105658.


References
1.
Henderson V, Paganini-Hill A, Miller B, Elble R, Reyes P, Shoupe D . Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000; 54(2):295-301. DOI: 10.1212/wnl.54.2.295. View

2.
Resnick S, Henderson V . Hormone therapy and risk of Alzheimer disease: a critical time. JAMA. 2002; 288(17):2170-2. DOI: 10.1001/jama.288.17.2170. View

3.
Wallace D . A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005; 39:359-407. PMC: 2821041. DOI: 10.1146/annurev.genet.39.110304.095751. View

4.
Asthana S, Brinton R, Henderson V, McEwen B, Morrison J, Schmidt P . Frontiers proposal. National Institute on Aging "bench to bedside: estrogen as a case study". Age (Dordr). 2009; 31(3):199-210. PMC: 2734241. DOI: 10.1007/s11357-009-9087-2. View

5.
Khachaturian Z . Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann N Y Acad Sci. 1989; 568:1-4. DOI: 10.1111/j.1749-6632.1989.tb12485.x. View